Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [55]
In the citing paper
“most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles [359,360].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [360]
In the citing paper
“This often generates beneficial therapeutic activities,102 due to additive or synergistic pharmacological effects.103”
From QSAR without borders (2020) · cites this paper as [102]
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Research works printed but not linked: 1
- Hemrick–Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
Cited by
Items 601–700 of 1,000
Proteome Interrogation Using Nanoprobes To Identify Targets of a Cancer-Killing Molecule
Li, L., Zhang, Q., Liu, A., Li, X., Zhou, H., Liu, Y., & Yan, B. (2011) · Journal of the American Chemical Society · doi:10.1021/ja111137n · Cited by 21
Dong, E., Grayson, D. R., Guidotti, A., & Costa, E. (2009) · Epigenomics · doi:10.2217/epi.09.2 · Cited by 21
Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors
Azuaje, J., López, P., Iglesias, A., de la Fuente, R. A., Pérez-Rubio, J. M., García, D., Stępniewski, T. M., García-Mera, X., Brea, J. M., Selent, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11370-2 · Cited by 24
Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology
Da, C., Zhang, D., Stashko, M. A., Vasileiadi, E., Parker, R. E., Minson, K. A., Huey, M. G., Huelse, J. M., Hunter, D. M., Gilbert, T. S. K., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b08660 · Cited by 21
A Review on the Mechanism and Application of Keishibukuryogan
Tanaka, K., Chiba, K., & Nara, K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.760918 · Cited by 21
Bianchi, M. T., Clark, A. G., & Fisher, J. L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.020 · Cited by 24
Michl, J., Scharinger, C., Zauner, M., Kasper, S. F., Freissmuth, M., Sitte, H. H., Ecker, G. F., & Pezawas, L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.013 · Cited by 21
A suite of engineered mice for interrogating psychedelic drug actions
Chiu, Y.-T., Deutch, A. Y., Wang, W., Schmitz, G. P., Huang, K. L., Koçak, D. D., Llorach, P., Bowyer, K., Liu, B., Sciaky, N., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02375-0 · Cited by 22
Self-citationBashiri, G., Johnston, J. M., Evans, G. L., Bulloch, E. M. M., Goldstone, D. C., Jirgis, E. N. M., Kleinboelting, S., Castell, A., Ramsay, R. J., Manos‐Turvey, A., et al. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715017216 · Cited by 21
Paliperidone-loaded spherical solid lipid nanoparticles
Kumar, S., & Randhawa, J. K. (2014) · RSC Advances · doi:10.1039/c4ra03107e · Cited by 20
Johnsen, E., & Kroken, R. A. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312462275 · Cited by 23
Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs
Dwyer, D. S., Aamodt, E. J., Cohen, B. M., & Buttner, E. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00177 · Cited by 21
The Use of Computer Models in Pharmaceutical Safety Evaluation
Boyer, S. K. (2009) · Alternatives to Laboratory Animals · doi:10.1177/026119290903700505 · Cited by 22
Stip, É., Zhornitsky, S., Moteshafi, H., Létourneau, G., Stikarovska, I., Potvin, S., & Tourjman, V. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.027 · Cited by 20
Developing a complete pharmacology for AMPA receptors: A perspective on subtype-selective ligands
Fleming, J. J., & England, P. M. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.072 · Cited by 20
Priapism in Antipsychotic Drug Use: A Rare but Important Side Effect
Sinkeviciute, I., Kroken, R. A., & Johnsen, E. (2012) · Case Reports in Psychiatry · doi:10.1155/2012/496364 · Cited by 27
Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.
Stip, É., & Lungu, O. (2015) · Europe PMC (PubMed Central) · Cited by 21
Onali, P., & Olianas, M. C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301152 · Cited by 20
Ma, J., Ye, N., & Cohen, B. M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.040 · Cited by 20
Vardanyan, R., Vijay, G., Nichol, G. S., Liu, L., Kumarasinghe, I. R., Davis, P., Vanderah, T. W., Porreca, F., Lai, J. Y., & Hruby, V. J. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.065 · Cited by 21
Wang, K., Sun, J., Zhou, S., Wan, C., Qin, S., Li, C., He, L., & Yang, L. (2013) · PLoS Computational Biology · doi:10.1371/annotation/958d4c23-4f1e-4579-b6ef-8ae1f828b1dd · Cited by 20
Pharmacogenetic Testing to Predict Antipsychotic-Induced Weight Gain: A Systematic Review
Risselada, A., Mulder, H., Heerdink, E. R., & Egberts, T. C. G. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.67 · Cited by 19
Zhong, J., Liang, Y., Chen, Y., Zhang, J., Zou, X., Deng, J., Da, W., Sun, Y., & Li, M. (2021) · Foods · doi:10.3390/foods10081863 · Cited by 21
Zhao, Q., Xiong, S., Chen, C., Zhu, H.-P., Xie, X., Peng, C., He, G., & Han, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.972372 · Cited by 20
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107036 · Cited by 19
Psychedelic-like Activity of Norpsilocin Analogues
Sherwood, A. M., Burkhartzmeyer, E. K., Williamson, S. E., Baumann, M. H., & Glatfelter, G. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00610 · Cited by 19
Gattrell, W. T., Smith, C. P. S., & Smith, A. J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.010 · Cited by 19
How structure informs and transforms chemogenetics
Roth, B. L. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.01.016 · Cited by 19
Self-citationStructure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor
Fyfe, T. J., Kellam, B., Sykes, D. A., Capuano, B., Scammells, P. J., Lane, J. R., Charlton, S. J., & Mistry, S. N. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00864 · Cited by 23
Potential Molecular and Cellular Mechanism of Psychotropic Drugs
Seo, M. S., Scarr, E., Lai, C., & Dean, B. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.2.94 · Cited by 20
Nath, A., Zientek, M. A., Burke, B. J., Jiang, Y., & Atkins, W. M. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034645 · Cited by 19
Non-monotonic dynamics and crosstalk in signaling pathways and their implications for pharmacology
van Wijk, R., Tans, S. J., ten Wolde, P. R., & Mashaghi, A. (2015) · Scientific Reports · doi:10.1038/srep11376 · Cited by 19
1,2-Benzisoxazole compounds: a patent review (2009 – 2014)
Uto, Y. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1027192 · Cited by 19
Johnsen, E., Sinkeviciute, I., Løberg, E., Kroken, R. A., Hugdahl, K., & Jørgensen, H. A. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-241 · Cited by 20
Karbownik, M. S., Szemraj, J., Wieteska, Ł., Antczak, A. J., Górski, P., Kowalczyk, E., & Pietras, T. (2016) · Pharmacology · doi:10.1159/000444534 · Cited by 19
Naporra, F., Gobleder, S., Wittmann, H., Spindler, J., Bodensteiner, M., Bernhardt, G., Hübner, H., Gmeiner, P., Elz, S., & Straßer, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.042 · Cited by 18
Velasquez, D., Quines, C. B., Pistoia, R. P., Zeni, G. R., & Nogueira, C. W. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.12.024 · Cited by 18
Bello, F. D., Ambrosini, D., Bonifazi, A., Newman, A. H., Keck, T. M., Giannella, M., Giorgioni, G., Piergentili, A., Cappellacci, L., Cilia, A., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00677 · Cited by 18
Oña, G., & Bouso, J. C. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191212103330 · Cited by 19
Schmidt, D., Scharf, M. M., Sydow, D., Aßmann, E., Martí-Solano, M., Keul, M., Volkamer, A., & Kolb, P. (2021) · Molecules · doi:10.3390/molecules26030629 · Cited by 18
Reilly, M. T., Noronha, A., & Warren, K. R. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62619-6.00002-1 · Cited by 20
Discovery Formulations: Approaches and Practices in Early Preclinical Development
Bhattachar, S., Bender, D. M., Sweetana, S. A., & Wesley, J. A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1399-2_2 · Cited by 18
Characterization of C‐Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH‐1
Lluis, M., Wang, Y., Monzingo, A. F., Fast, W. L., & Robertus, J. D. (2010) · ChemMedChem · doi:10.1002/cmdc.201000392 · Cited by 18
Del’Guidice, T., & Beaulieu, J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046540 · Cited by 18
Naumovska, Z., Nesterovska, A. K., Filipce, A., Sterjev, Z., Brezovska, K., Dimovski, A. J., & Šuturkova, L. (2015) · PRILOZI · doi:10.1515/prilozi-2015-0030 · Cited by 19
Access to the CNS: Biomarker Strategies for Dopaminergic Treatments
van den Brink, W. J., Palić, S., Köhler, I., & de Lange, E. C. M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2333-x · Cited by 19
Wang, M., Cheng, X., Chen, X., Li, Y., Zang, L., Duan, Y., Chen, M., Yu, P., Sun, H., & Wang, R. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13331 · Cited by 18
Rafi, H., Rafiq, H., & Farhan, M. (2021) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-021-00118-7 · Cited by 24
Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia
Frost, E. D., Shi, S. X., Byroju, V. V., Rissardo, J. P., Donlon, J., Vigilante, N. F., Murray, B. P., Walker, I. M., McGarry, A. J., Ferraro, T. N., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14121163 · Cited by 17
Virtual Affinity Fingerprints for Target Fishing: A New Application of Drug Profile Matching
Peragovics, Á., Simon, Z., Tombor, L., Jelinek, B., Hári, P., Czobor, P., & Málnási‐Csizmadia, A. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3004489 · Cited by 20
Machine Learning Technique Approaches in Drug Discovery, Design and Development
Pugazhenth, D., & Rajagopala, S. P. (2007) · Information Technology Journal · doi:10.3923/itj.2007.718.724 · Cited by 17
Ligand-Target Prediction by Structural Network Biology Using nAnnoLyze
Martínez-Jiménez, F., & Martí-Renom, M. A. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004157 · Cited by 18
Romeo-Guitart, D., & Casas, C. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.251187 · Cited by 17
Towards the routine use of in silico screenings for drug discovery using metabolic modelling
Bintener, T., Pacheco, M. P., & Sauter, T. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190867 · Cited by 18
Yang, Z., Ma, H., Sun, Z., Luo, L., Tian, S., Zheng, J., & Zhang, X. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.049 · Cited by 17
Screening for Safety‐Relevant Off‐Target Activities
Urbán, L., Whitebread, S., Hamon, J., Mikhailov, D., & Azzaoui, K. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch2 · Cited by 17
Synthesis and leishmanicidal activity of quinoline–triclosan and quinoline–eugenol hybrids
Arango, V., Domínguez, J. J., Cardona, W., Robledo, S. M., Muñoz, D. L., Figadère, B., & Sáez, J. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9886-8 · Cited by 17
Strategies for pharmacotherapy of schizophrenia
Arnt, J., Bang‐Andersen, B., Dias, R. D. S., & Bøgesø, K. P. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.09.1236966 · Cited by 17
Brunhofer, G., Studenik, C. R., Ecker, G. F., & Erker, T. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.10.005 · Cited by 17
How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses
Marques, T. R., Levine, S. Z., Reichenberg, A., Kahn, R. S., Derks, E. M., Fleischhacker, W., Rabinowitz, J., & Kapur, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.04.001 · Cited by 18
The Ketogenic Diet Revisited: Beyond Ketones
Sourbron, J., Thevissen, K., & Lagae, L. G. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.720073 · Cited by 19
Barcode Sequencing for Understanding Drug–Gene Interactions
Smith, A. M., Durbic, T., Kittanakom, S., Giaever, G. N., & Nislow, C. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-965-5_4 · Cited by 18
Yoon, S., Noh, J. S., Choi, S., & Baik, J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.108 · Cited by 23
Heusler, P., Slot, L. A. B., Tourette, A., Tardif, S., & Cussac, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.031 · Cited by 17
Vogt, A., & Lazo, J. S. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.002 · Cited by 17
“Network Target” Theory and Network Pharmacology
Li, S., Ding, Q., & Wang, X. (2021) · Springer eBooks · doi:10.1007/978-981-16-0753-0_1 · Cited by 16
Li, C., Tian, H., Li, R., Jia, F., Wang, L., Ma, X., Yang, L., Zhang, Q., Zhang, Y., Yao, K., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.096 · Cited by 17
Cortés-Cabrera, Á., Morris, G. M., Finn, P. W., Morreale, A., & Gago, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12294 · Cited by 19
Synergistic Synthetic Biology: Units in Concert
Trosset, J., & Carbonell, P. (2013) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2013.00011 · Cited by 16
Gakh, A. A., Sosnov, A. V., Krasavin, M., Nguyen, T. L., & Hamel, E. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.007 · Cited by 16
Liggi, S., Drakakis, G., Hendry, A. E., Hanson, K., Brewerton, S. C., Wheeler, G. N., Bodkin, M. J., Evans, D. A. P., & Bender, A. (2013) · Molecular Informatics · doi:10.1002/minf.201300102 · Cited by 20
Liebig, M., Gossel, M., Pratt, J., Black, M. D., Haschke, G., Elvert, R., Juretschke, H., Neumann‐Haefelin, C., Kramer, W., & Herling, A. W. (2010) · Obesity · doi:10.1038/oby.2010.17 · Cited by 16
Flood, D. G., Zuvich, E., Marino, M. J., & Ga̧sior, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2196-5 · Cited by 16
Szabó, M., Lim, H. D., Herenbrink, C. K., Christopoulos, A., Lane, J. R., & Capuano, B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5013243 · Cited by 17
Binding site comparisons for target-centered drug discovery
Konc, J. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1588883 · Cited by 16
Mitazaki, S., Nakagawasai, O., Onogi, H., Watanabe, K., Takahashi, K., Tan–No, K., Quirion, R., Srivastava, L. K., & Tadano, T. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112226 · Cited by 16
Clark, P. J., Brodnik, Z. D., & España, R. A. (2022) · The Neuroscientist · doi:10.1177/10738584221134587 · Cited by 17
Developing kinase inhibitors for malaria: an opportunity or liability?
Mogwera, K. S. P., Chibale, K., & Arendse, L. B. (2023) · Trends in Parasitology · doi:10.1016/j.pt.2023.06.001 · Cited by 16
Scarlota, L., Harvey, J. A., & Aloyo, V. J. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1928-2 · Cited by 16
Li, W., Wan, X., Zeng, F., Xie, Y., Wang, Y., Zhang, W., Li, L., & Huang, N. (2014) · MedChemComm · doi:10.1039/c4md00030g · Cited by 16
Potential of GPCR-Targeting Insecticides for Control of Arthropod Vectors
Sharan, S., & Hill, C. A. (2017) · ACS symposium series · doi:10.1021/bk-2017-1265.ch004 · Cited by 18
Multiscale Virtual Screening Optimization for Shotgun Drug Repurposing Using the CANDO Platform
Hudson, M. L., & Samudrala, R. (2021) · Molecules · doi:10.3390/molecules26092581 · Cited by 16
Talevi, A., & Bruno‐Blanch, L. E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6464-8_14 · Cited by 19
Hassan, L., Frisher, M., Senior, J., Tully, M. P., Webb, R. T., While, D., & Shaw, J. J. (2014) · Health Services and Delivery Research · doi:10.3310/hsdr02330 · Cited by 19
In SilicoFunctional Profiling of Small Molecules and Its Applications
Sato, T., Matsuo, Y., Honma, T., & Yokoyama, S. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800504q · Cited by 16
Indoloquinolizidine–Peptide Hybrids as Multiple Agonists for D1 and D2 Dopamine Receptors
Vendrell, M., Soriano, A., Casadó, V., Díaz, J. L., Lavilla, R., Canela, E. I., Lluís, C., Franco, R., Alberício, F., & Royo, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200900149 · Cited by 16
Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery
Milelli, A., Turrini, E., Catanzaro, E., Maffei, F., & Fimognari, C. (2016) · Drug Development Research · doi:10.1002/ddr.21334 · Cited by 17
A ranking method for the concurrent learning of compounds with various activity profiles
Dörr, A., Rosenbaum, L., & Zell, A. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-014-0050-6 · Cited by 15
Turanlı, Y., Birer, M., Turgut, Y., Uyar, R., Yurdakök-Dikmen, B., & Acartürk, F. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105262 · Cited by 15
Integrative Pharmacology in the Treatment of Substance Use Disorders
Donlon, J., Kumari, P., Varghese, S. P., Bai, M. Y., Florentin, O. D., Frost, E. D., Banks, J., Vadlapatla, N., Kam, O., Shad, M. U., et al. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2293854 · Cited by 17
Manen-Freixa, L., & Antolín, A. A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2376643 · Cited by 15
A network-oriented perspective on cardiac calcium signaling
George, C. H., Parthimos, D., & Silvester, N. C. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00388.2011 · Cited by 15
Altamura, A. C., Armadoros, D., Jaeger, M., Kernish, R., Locklear, J. C., & Volz, H. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802250056 · Cited by 16
Balcıoğlu, Y. H., Gökçay, H., & Yeşilkaya, Ü. H. (2020) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000404 · Cited by 16
Drugs, host proteins and viral proteins: how their promiscuities shape antiviral design
Gupta, M. N., & Roy, I. (2020) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12652 · Cited by 15
McKenna, D. J., Ruiz, J. M., Hoye, T. R., Roth, B. L., & Shoemaker, A. T. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.12.037 · Cited by 15
Self-citationShort-Term Treatment of Catatonia With Amantadine in Schizophrenia and Schizoaffective Disorder
de Lucena, D. F., Pinto, J. P., Hallak, J. E. C., Crippa, J. A. S., & Gama, C. S. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825ebf6e · Cited by 15
8-Sulfonyl-substituted tetrahydro-1 H -pyrido[4,3- b ]indoles as 5-HT 6 receptor antagonists
Ivachtchenko, A. V., Mitkin, O. D., Tkachenko, S. E., Okun, I. M., & Kysil, V. M. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.10.035 · Cited by 15
Veselinović, T., Schorn, H., Vernaleken, I., Schiffl, K., Hiemke, C., Zernig, G., Gur, R. C., & Gründer, G. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2368-3 · Cited by 17
Structure-guided design of a peripherally restricted chemogenetic system
Kang, H. J., Krumm, B. E., Tassou, A., Geron, M., DiBerto, J. F., Kapolka, N. J., Gumpper, R. H., Sakamoto, K., Koçak, D. D., Olsen, R. H. J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.11.001 · Cited by 14
Self-citation
Metadata
- Authors
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 353-359
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2122995608
- Cited by
- 1,155
- References
- 63
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 37 · 2023: 39 · 2022: 47 · 2021: 49 · 2020: 49 · 2019: 63 · 2018: 46 · 2017: 42 · 2016: 61 · 2015: 65 · 2014: 58 · 2013: 73 · 2012: 83
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- magic bullet, polygenic disease, mood disorders, schizophrenia, depression, bipolar disorder, central nervous system disorders, drug target selectivity, polypharmacology, antipsychotic drug development
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents, Drugs, Investigational, Comorbidity, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.